Scienture Holdings, Inc. - Common Stock SCNX 深 滬
已收盤 10-31 16:00:00 美东时间
0.776
+0.008
+1.08%
華盛通- 最 高1.10
- 今 開0.75
- 成交量 1965.52万股
- 最 低 0.75
- 昨 收 0.7677
- 總市值 1913.48万
- 52周最高 8.72
- 市盈率 靜 --
- 換手率 79.71%
- 52周最低 0.461
- 委 比 96.19%
- 總股本 2465.82万
- 歷史最高 164.50
- 量 比 0.89
- 振 幅 45.59%
- 歷史最低 -5.81
- 每 手 1
- 風險率 2.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Shares of Intel Corporation (NASDAQ:INTC) rose sharply in pre-market trading af...
10-24 17:25
Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?
Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are rising Thursday after the company announced the start of commercial sales for Arbli.
10-24 01:14
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
Scienture Holdings launched Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium, to address unmet market needs. The U.S. losartan market totals $256 million annually with 71 million prescriptions, presenting a significant opportunity. Arbli™ offers a safe, consistent, and convenient alternative to solid dosage forms, particularly for patients requiring liquid formulations. Scientific secured PBM-GPO agreements for ex...
10-23 12:05
Scienture Holdings Faces Nasdaq Non-Compliance Notice
Scienture Holdings ( ($SCNX) ) has shared an announcement. On October 14, 2025,...
10-18 05:30
SCIENTURE HOLDINGS Says Arbli Oral Suspension, 10mg/mL, Is Commercially Available Through Full-Line Wholesalers Nationwide
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tabletsU.S. losartan market totals $256M annually with 71M prescriptions, creating a significant
10-16 21:04
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
<p>SCIENTURE HOLDINGS, INC. announced the commercial availability of Arbli<sup>™</sup> (losartan potassium) Oral Suspension, the first FDA-approved ready-to-use liquid losartan formulation for patients with dysphagia, including elderly patients and children as young as six. The U.S. losartan market totals $256M annually with 71M prescriptions, presenting a significant opportunity for Arbli<sup>™</sup>. Arbli<sup>™</sup> addresses critical patient...
10-16 13:00
Wellgistics Health reappoints Prashant Patel as interim CEO amid executive shakeup
Prashant Patel, has been reappointed as president, interim cheif executive officer, and board member of Wellgistics Health (NASDAQ:WGRX) after resigning from similar roles in August 2025. Eric Sherb, ...
10-13 20:14
SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) announced an agreement with Arena Investors to discharge all outstanding balances on convertible debentures. The conversion price was amended to $2.4861 per share, with remaining amounts to be converted into common stock. All obligations under the debentures have been deemed paid in full, and related security interests have been released. The transaction strengthens the company's balance sheet, eliminates i...
10-08 13:00
Scienture Holdings Amends Bylaws for Quorum Change
Scienture Holdings ( ($SCNX) ) has shared an announcement. On October 1, 2025, ...
10-07 05:50
Scienture Holdings Amends Convertible Debentures Agreement
Scienture Holdings ( ($SCNX) ) has provided an update. On October 3, 2025, Scie...
10-04 05:19
